The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
BVX-0922 to target colorectal cancer under investigator-sponsored IND
Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
This is the sixth successful USFDA audit for this facility
The SMILE-100 System is a breast thermography device that helps healthcare personnel review, measure and analyze thermally significant indications in the breast region
Subscribe To Our Newsletter & Stay Updated
